Write a 100-350 word essay about human UGT1A9: it function, reaction pathways it participates in, where it is located and diseases related to it.  Provide 3-5 key references where I can find more information.

Human UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9) is a critical enzyme in the body's detoxification system. As a member of the UDP-glucuronosyltransferase (UGT) family, UGT1A9 plays a key role in the glucuronidation process, a major phase II metabolic pathway. This process involves the conjugation of glucuronic acid to a variety of substrates, including drugs, environmental toxins, and certain endogenous compounds, which increases their water solubility and facilitates their excretion from the body.

UGT1A9 is primarily located in the liver, although it is also expressed in other tissues such as the kidney and gastrointestinal tract. The enzyme is particularly important for the metabolism and detoxification of a broad range of pharmaceuticals and xenobiotics. By attaching glucuronic acid to these compounds, UGT1A9 enhances their solubility, aiding in their removal from the body and reducing their potential toxicity.

The activity of UGT1A9 and its genetic polymorphisms can significantly influence an individual's ability to metabolize certain medications. These genetic differences can lead to variability in drug efficacy and toxicity among patients, affecting treatment outcomes. For example, individuals with specific UGT1A9 polymorphisms may exhibit altered metabolism of drugs that are UGT1A9 substrates, requiring adjustments in drug dosing to achieve therapeutic effectiveness or to avoid adverse effects.

Abnormal UGT1A9 function has been linked to various diseases. For instance, reduced UGT1A9 activity may contribute to Gilbert's syndrome, a condition characterized by mild unconjugated hyperbilirubinemia. In addition, UGT1A9's role in processing potentially carcinogenic compounds suggests its involvement in cancer risk and development.

For more detailed information on UGT1A9, its function, and related diseases, the following key references are recommended:

1. Tukey, R.H., & Strassburg, C.P. (2000). "Human UDP-glucuronosyltransferases: Metabolism, expression, and disease." Annual Review of Pharmacology and Toxicology, 40, 581-616.

2. Guillemette, C. (2003). "Pharmacogenomics of human UDP-glucuronosyltransferase enzymes." Pharmacogenomics Journal, 3(3), 136-158.

3. Basu, N.K., et al. (2004). "Human UDP-glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol conjugation." Drug Metabolism and Disposition, 32(9), 1081-1087.

4. Court, M.H. (2005). "Interindividual variability in hepatic drug glucuronidation: Studies with UDP-glucuronosyltransferase polymorphic variants." Pharmacogenomics, 6(3), 341-359.

5. Wiener, D., et al. (2004). "Regulation and function of UDP-glucuronosyltransferases in drug metabolism and disease." Drug Metabolism Reviews, 36(3-4), 503-523.

These references provide insights into the biochemical role of UGT1A9 in the glucuronidation process, its importance in drug metabolism, and the implications of genetic variability in diseases such as Gilbert's syndrome and its potential role in cancer risk and progression.